Country comparison
CAR-T in China vs the UK
7 min read · Last verified: 2026-09-09
How CAR-T access works in the UK
In the UK, CAR-T is NHS-funded but tightly protocolised. NICE appraises each product for clinical and cost-effectiveness; NHS England then commissions delivery at a small number of specialist centres. As of 2025 there are 20 NHS England-commissioned adult CAR-T centres, and nearly 400 patients were treated between April 2024 and March 2025 (NHS England figures, published in an ICO decision notice).
What is funded, as of September 2026:
- Tisagenlecleucel for relapsed or refractory B-cell acute lymphoblastic leukaemia in people up to 25 (NICE TA554, 2018).
- Tisagenlecleucel for relapsed or refractory DLBCL after two or more systemic therapies (TA567, 2019).
- Axicabtagene ciloleucel for relapsed or refractory DLBCL and primary mediastinal large B-cell lymphoma after two or more therapies (TA872, 2023) — list price £280,451 per infusion, but free at the point of care for eligible patients — and for DLBCL after first-line chemoimmunotherapy in defined circumstances (TA895, 2023).
What is not funded matters just as much. NICE was unable to recommend ciltacabtagene autoleucel (Carvykti) for multiple myeloma after the company withdrew its evidence submission (TA889, 2023) — so there is no routine NHS CAR-T pathway for myeloma as of this writing.
Eligibility is decided by multidisciplinary teams against the exact NICE criteria. If your disease, prior lines of therapy, and fitness match, the NHS pays for everything. A private route exists in principle but is rarely used, and private prices are not published.
When UK patients look at China
- Myeloma. With no NICE-funded BCMA CAR-T, myeloma patients are the clearest group. China has NMPA-approved BCMA products in routine commercial use.
- Outside the licensed box. The wrong subtype, the wrong line of therapy, or protocol criteria that exclude you from the NHS pathway.
- Timing. Referral, panel approval, and manufacturing slots all take time; some patients are told the disease will not wait.
A self-funded China journey typically totals $170,000–260,000, with product list prices of $140,000–180,000 (site dataset, NMPA list prices, verified 2026-07). See the itemized cost page.
The honest trade-offs
If NICE funds your indication, staying home is almost certainly the right call. Free treatment at a commissioned centre accountable to the NHS, with follow-up inside your own health system, is a combination no self-paid journey beats.
If you do travel, plan for six to ten weeks abroad, with the highest-risk days straight after infusion spent far from home. Follow-up becomes a handoff: your NHS haematology team must agree to accept a bilingual discharge package and a monitoring plan written elsewhere. Sort that agreement out before you commit — a discharge plan nobody at home will manage is a clinical risk, not a paperwork detail.
Questions to ask your treating team
- Is my exact diagnosis and treatment history within a NICE-funded indication? Which guidance applies to me?
- If not, is there an NHS clinical trial, or a funding panel route worth trying?
- If I self-fund treatment abroad, will this team accept the follow-up plan — and what documentation would you need?
- Clinically, what does waiting for a local slot cost me compared with travelling now?
Where to go next
Sources
Compare with another country